Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3220158 | 0.91 | ALOX15 (0.35) | SMYD3RAD52HRH3TP53CYP1A2 | |
| SCHEMBL3225086 | 0.87 | HRH3 (0.35) | SMYD3RAD52HRH3TP53CYP1A2 | |
| SCHEMBL3225680 | 0.83 | ALOX15 (0.34) | SMYD3RAD52HRH3TP53CYP1A2 | |
| SCHEMBL3218711 | 0.78 | KDM1A (0.33) | SMYD3RAD52HRH3TP53CYP1A2 | |
| SCHEMBL26071651 | 0.72 | PSEN1 (0.44) | — | |
| SCHEMBL4354178 | 0.69 | SMYD3 (0.41) | SMYD3HRH3CYP1A2MBTD1L3MBTL1 | |
| SCHEMBL5596703 | 0.69 | SMYD3 (0.39) | SMYD3SMN1; SMN2 | |
| SCHEMBL4202177 | 0.68 | HRH3 (0.42) | SMYD3HRH3CYP1A2SMN1; SMN2KCNH2 | |
| SCHEMBL4207692 | 0.66 | SMYD3 (0.39) | SMYD3HRH3CYP1A2MBTD1L3MBTL1 | |
| SCHEMBL10167789 | 0.66 | HRH3 (0.43) | HRH3CYP1A2CYP2D6MBTD1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063049-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2010-03-11 | — | — | US | disclosed |
| EP-2029578-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZ0LYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007138277-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZ0LYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063049-A1 | 2-CARBOCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHBITION OF CELL PROLIFERATION | MKI67, CCNI, CDK2 | SMYD3 4220/4885RAD52 1086/4885HRH3 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.